{
    "clinical_study": {
        "@rank": "141180", 
        "arm_group": [
            {
                "arm_group_label": "1 dose varicella vaccine", 
                "arm_group_type": "Active Comparator", 
                "description": "The providers would get the 2nd dose since they had one dose varicella vaccine"
            }, 
            {
                "arm_group_label": "2 dose varicella vaccine", 
                "arm_group_type": "Experimental", 
                "description": "The provider never get the varicella vaccine"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the safety, immunogenicity and immune effect of the Varicella vaccine after\n      the 2nd dose vaccination in Chao yang district, Bei jing, since the 2nd varicella\n      vaccination was promoted by Beijing Center for Disease Control and Prevention in November,\n      2012."
        }, 
        "brief_title": "The Safety, Immunogenicity and Immune Effect Research of the Varicella Vaccine After the 2nd Dose Vaccination", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Varicella", 
        "condition_browse": {
            "mesh_term": [
                "Chickenpox", 
                "Herpes Zoster"
            ]
        }, 
        "detailed_description": {
            "textblock": "\"Breakthrough\" varicella cases and varicella cases were monitored to evaluate the protective\n      effective in a large population.\n\n      Make the basic evaluation of safety for the two dose of varicella vaccination\n\n      Monitoring the Varicella virus origin and virus types from illness cases in Chao yang\n      district\n\n      Make the evaluation of healthy costs reduce for the varicella emergency vaccination after\n      large number of varicella cases occurred."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participants were between 4-12 years old\n\n          -  Participants were in good healthy determined through medical history, physical\n             examination, clinical judgment of the investor\n\n        Exclusion Criteria:\n\n          -  Having a fever (axillary temperature \uff1e37.0\u2103) before enrollment;\n\n          -  Having a disease history of seizures, brain and mental disease and the vaccination\n             history of allergies and convulsions;\n\n          -  Antibiotics allergy;\n\n          -  Having a problem of intramuscular injection because thrombocytopenia or other blood\n             coagulation disorder;\n\n          -  Having immunodeficiency or under immunosuppression therapy, radiation therapy;\n\n          -  Having respiratory diseases, acute infection, chronic disease and HIV infection;\n\n          -  Having systemic skin rash, skin tinea, herpes;\n\n          -  Chronic liver and kidney disease;\n\n          -  Heart disease, and severe hypertension;\n\n          -  Have received whole blood, plasma or immunoglobulin therapy 3 months before\n             enrollment;\n\n          -  Have not received other vaccination in 7 days before enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "12 Years", 
            "minimum_age": "4 Years"
        }, 
        "enrollment": {
            "#text": "50000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01830283", 
            "org_study_id": "BJCDPC-8"
        }, 
        "intervention": {
            "arm_group_label": [
                "1 dose varicella vaccine", 
                "2 dose varicella vaccine"
            ], 
            "description": "The providers would get varicella vaccine", 
            "intervention_name": "varicella vaccine", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "Beijing Chaoyang District Centers for Disease Control and Prevention"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 4 Study of the Varicella Vaccine After the 2nd Dose Vaccination", 
        "other_outcome": {
            "description": "Antibody titre of varicella vaccine after 2 dose injection", 
            "measure": "Antibody titre of varicella vaccine after 2 dose injection", 
            "safety_issue": "No", 
            "time_frame": "6 monthes"
        }, 
        "overall_official": {
            "affiliation": "Beijing Chaoyang District Centers for Disease Control and Prevention", 
            "last_name": "Nianmin Shi", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Detection the Varicella virus origin and virus types from illness cases in Chao yang district", 
            "measure": "Incidence of varicella after 2 dose vaccination", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01830283"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Adverse event rate of varicella vaccine after 2 dose injection", 
            "measure": "Adverse event rate of varicella vaccine after 2 dose injection", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "source": "Beijing Center for Disease Control and Prevention", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing Center for Disease Control and Prevention", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}